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Abstract
The purpose of this study was to determine whether trans-
catheter arterial chemoembolization (TACE) protocol affects
the total volume of chemotherapy injected into the liver as
well as subsequent arterial patency. A total of 160 patients
with primary or secondary liver cancer were treated with 3
different chemoembolization protocols at a single institution.
Data were analyzed retrospectively. Group 1 (n  36) con-
sisted of slurry of chemotherapy, oil and polyvinyl alcohol
particles (PVA), group 2 (n  91), chemotherapy and oil
followed by PVA, and group 3 (n 33), chemotherapy and oil
followed by Gelfoam pledgets. The total volume of chemother-
apy injected into the liver was recorded. Arterial patency was
determined during subsequent chemoembolizations. The mean
percentage of total intended chemotherapy dose administered
was 54.6% for group 1, 75.3% for group 2, and 80.6% for group
3. Arterial patency at follow-up angiography was 56% for
group 1, 74% for group 2, and 81% for group 3. The slurry
protocol (group 1) significantly reduced arterial patency and
injectable volume of chemotherapy during TACE.
Key words: Liver neoplasms—Chemotherapeutic emboliza-
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The management of patients with advanced primary or met-
astatic liver cancer remains extremely challenging. Despite
the development of new treatment modalities, clinical out-
comes are typically poor. Few therapeutic options are effec-
tive, especially since neither conventional systemic
chemotherapy nor radiation therapy can halt the progression
of disease [1–3]. Transcatheter arterial chemoembolization
(TACE), which consists of delivering a mixture of ethio-
dized oil, chemotherapeutic agents and embolic particles
directly to the tumor, is commonly performed to treat these
types of liver cancer. TACE is particularly effective in
providing symptomatic relief and prolonging the life of
patients with neuroendocrine tumors, especially those of the
carcinoid type [4]. In addition, multiple studies, through
neither randomized nor prospective, have shown TACE to
have a survival benefit in patients with hepatocellular carci-
noma when compared to historical data [5–11]. This survival
benefit was accompanied by significant tumor response, as
demonstrated by a reduction in tumor volume on imaging
studies and in tumor marker levels after TACE [8–11].
Several randomized controlled trials comparing TACE to
supportive care have failed to demonstrate a statistically
significant survival benefit of TACE [9, 12–14]. As de-
scribed in a forthcoming meta-analysis of these trials, it is
likely that severe methodological deficiencies inherent to
these studies underlie their failure to validate TACE [15].
Recently, two rigorous, randomized, controlled trials have
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demonstrated a survival benefit associated with chemoem-
bolization [16, 17]. The exacting nature of the protocols used
in these trials underscores the importance of the chemoem-
bolization procedure in achieving good outcomes.
Although many different chemoembolization protocols
have been used in the past [8–14, 18], the combination of
some chemotherapeutic agents and a vehicle such as iodized
oil constitutes the basis of most TACE procedures. An
embolic material consisting of either polyvinyl alcohol
(PVA) or Gelfoam particles is usually added next. These
embolic agents produce different effects on vasculature,
since PVA causes permanent or semi-permanent occlusion,
whereas Gelfoam causes temporary occlusion with recana-
lization taking place within 2 weeks [19]. Given these prop-
erties of these embolic agents, use of a particular embolic
agent may affect the actual amount of chemoembolization
mixture administered into the tumor, potentially causing
permanent arterial occlusion, thereby compromising arterial
access for subsequent TACE. The choice of embolic mate-
rial—PVA or Gelfoam particles—as well as the manner in
which these agents are delivered—slurry of chemotherapy,
oil and embolic particles or chemotherapeutic agents and oil
followed by embolic material—may therefore play a critical
role in the success of TACE. The purpose of this study was
to assess whether the choice of TACE protocol and embolic
material would affect 1) the amount of chemotherapy actu-




Between August 1995 and December 2001, 385 TACE procedures
were performed at a single institution on 160 patients with unre-
sectable primary or secondary liver cancer. Each patient provided
informed consent prior to each TACE procedure; the data were
analyzed retrospectively to assess changes in TACE protocol at our
institution. The type of tumor was consistent among all groups
(Table 1). Of these patients, 121 had at least one repeat hepatic
arteriogram during a subsequent TACE procedure that demon-
strated the status of arterial supply to the tumor. The 39 patients
who underwent only one TACE procedure without further arterio-
grams were excluded from this study because the patency of the
arterial supply to the tumor could not be assessed angiographically.
Most patients with metastatic liver cancer treated with TACE failed
to respond to conventional systemic chemotherapy, resulting in
tumor progression. As described by Chung [19], we could safely
perform selective (segmental or sub-segmental) TACE for patients
with small tumors who have poor liver function (Child-Pugh class
C). Main portal vein thrombosis was not considered an absolute
contraindication to chemoembolization, but special precautions
were taken to minimize the use of embolic particles in order to
reduce the risk of hepatic necrosis or infarct. However, patients
demonstrating the constellation of a massive tumor combined with
severe portal vein invasion and poor liver function were not offered
TACE. The characteristics of the patient population are given in
Table 1.
Chemoembolization Protocol
After obtaining arterial access, a diagnostic visceral arteriogram
was performed to delineate the arterial supply to the tumor, deter-
mine the presence of variant arterial anatomy, and confirm portal
vein patency. As stated earlier, portal vein thrombosis did not
necessarily constitute a contraindication to performing TACE. A
catheter was then advanced selectively into the right or left hepatic
artery, distal to the cystic artery. Patients with multiple or diffuse
lesions received lobar embolizations. Using a microcatheter to
select a second or third-order branch of the right or left hepatic
artery, patients with unifocal tumors were treated with selective
chemoembolization. The proportion of patients treated with super-
selective chemoembolization is shown in Table 1.
After having safely positioned the catheter within the artery
feeding the tumor, the chemoembolization mixture was infused into
the artery. The same three chemotherapeutic agents were used
consistently at our institution (based on the Hospital of the Univer-
sity of Pennsylvania protocol), regardless of tumor type. This
regimen was comprised of cisplatin 100 mg (Bristol Myers Squibb,
Princeton, NJ), doxorubicin 50 mg (Adriamycin; Pharmacia-Up-
john, Kalamazoo, MI) and mitomycin C 10 mg (Bedford Labora-
tories, Beford, OH) mixed in 10 ml of water-soluble contrast
medium (Omnipaque; Winthrop Pharmaceuticals, New York, NY).
After having received the chemotherapy from the pharmacy, it was
consistently mixed with an equivalent volume of ethiodized oil.
Table 1. Patient characteristics and results for each group
Group 1 Group 2 Group 3
Number of patients 36 91 33
Mean age 63.1 59.6 62.1
Mean lesion diameter (cm) 7.2 8.3 7.9
Patients with portal vein thrombosis 3 (8%) 8 (9%) 3 (9%)
Patients with HCC 24 (67%) 56 (62%) 21 (64%)
Patients with colorectal cancer 2 (6%) 4 (4%) 1 (3%)
Patients with neuroendocrine tumors 6 (17%) 17 (19%) 6 (18%)
Patients with hypervascular tumors 32 (89%) 85 (93%) 31 (94%)
Super-selective chemoembolizations 6 (17%) 13 (14%) 6 (18%)
Intended chemotherapy volume (ml) 8.5 8.5 8.5
Mean volume injected (percentage) (55%) (75%) (81%)
Patients receiving total volume 7 (19%) 78 (86%) 30 (91%)
Vessel recanalization 56% 74% 81%
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Study Groups
Patients were treated with three different chemoembolization pro-
tocols. In group 1 (n  36 patients), PVA particles (0.1–0.2 cc of
150–250 m dry particles; Boston Scientific Medi-tech, Natick,
MA) were mixed with the chemotherapy-oil mixture at the begin-
ning of the procedure and injected as part of a slurry throughout the
procedure. In group 2 (n  91), PVA particles (150–250 m) were
administered after injection of the chemotherapy-oil mixture. In
group 3 (n  33), small pledgets of gelatin sponge (Gelfoam;
Upjohn, Kalamazoo, MI) were used for particle embolization after
administration of the total dose of the chemotherapy-oil mixture. In
all groups, the chemotherapy was mixed in a 1:1 volume ratio with
lipiodol. The only difference between groups 2 and 3 was the type
of embolic agent used (PVA for group 2, Gelfoam for group 3). The
mean volumes of chemotherapy, delivered by the pharmacy, were
identical for all groups. The goal of therapy for all patients was to
administer the entire intended dose (all 20 ml) of chemotherapy and
oil mixture. The procedure was stopped either at the point of near
stasis within the main artery feeding the tumor (approximately 90%
reduction of flow) or after the entire amount of chemotherapy was
administered, in which case the main vessel remained mostly
patent. For groups 2 and 3, embolic agents were consistently
delivered at the end of the procedure.
Nearly identical proportions of tumor types, tumor sizes, portal
venous thrombosis and degrees of hypervascularity at angiography
among the three groups (Table 1) ensure that these variables would
not confound arterial patency data. Seven patients had colorectal
metastases (2, 4, and 1 in groups 1–3, respectively), 29 patients had
neuroendocrine tumors (6, 17, and 6 in groups 1–3), and 101 had
hepatocellular carcinoma (24, 56, and 21 in groups 1–3). The mean
greatest transverse tumor diameter measured by CT or MRI was
7.2, 8.3, and 7.9 cm for each group, respectively. Fourteen patients
presented with portal vein thrombosis (3, 8, and 3 in groups 1–3,
respectively). All three groups had comparable proportions of hy-
pervascular tumors (89%, 93%, 94% for each group, respectively).
The mean interval between consecutive arteriograms was 9  0.4
weeks for group 1, 7  0.2 weeks for group 2, and 7  0.2 weeks
for group 3. Note that differences in follow-up are largely due to
scheduling issues and were not related to the patency of the vessels
or the status of the liver.
In order to assess arterial patency, arteriograms obtained during
each chemoembolization procedure were reviewed simultaneously
by two experienced interventional radiologists blinded to both the
type of particle embolization used during the procedure and the
TACE protocol. Patency was assessed based on recanalization of
previously embolized arteries. All patients underwent a celiac or
common hepatic arteriogram if not superselective catheterization at
follow-up to assess the patency of previously treated vessels. A
vessel was considered patent or recanalized when forward flow
extending into the hepatic parenchyma or the tumor itself was
identified. Each treated vessel was considered patent or nonpatent at
follow-up. The same artery or arteries feeding the tumor was
assessed for patency after each chemoembolization; in this manner,
baseline pre-TACE arterial flow could be compared to arterial flow
at follow-up in the same patient. Using this method, we could
assess both the flow of main feeding vessels and overall tumor
vascularity. A tumor was considered hypervascular when an area of
tumor blush uniformly hyperattenuating to liver parenchyma was
identified. Areas of tumor blush corresponded to the known loca-
tion of the tumor on cross-sectional imaging.
The actual volume of chemoembolization mixture (either slurry
of chemotherapy, oil and particles or chemotherapy and oil alone)
as well as the volume of chemotherapy administered during each
procedure was obtained immediately following each TACE proce-
dure from dictated procedural reports. The amount of chemotherapy
actually injected into the tumor was then expressed as a percentage
of the total volume of chemotherapy retrieved from the pharmacy.
Occasionally, the embolic effects of ethiodol would preclude ad-
ministration of a complete dose of chemotherapy for patients in
groups 2 and 3; these patients still received PVA or Gelfoam
particles following injection of chemotherapy, ensuring protocol
consistency.
Data Analysis
Proportions from each of the three groups were compared to each
other using 2-sample Z tests. All P values are two-tailed. Statistical
significance was established when P 0.05. All data ranges shown
indicate the standard deviation of a given data set. Chi-square
cross-tabulation tests were used to evaluate differences between the
groups in age, gender, race, proportion of patients with hepatocel-
lular carcinoma, tumor vascularity, interval between procedures
and tumor size. None of these variables approached statistical
significance.
Results
Patients treated with the slurry of chemotherapy, lipiodol,
and PVA particles (group 1, n  36) received a significantly
lower dose of chemotherapy than those treated with either
PVA or Gelfoam, administered at the end of the procedure
(groups 2 (n  91) and 3 (n  33), respectively). The mean
volume of chemotherapy administered to patients in group 1
was 55  4% (5.0/9.0 ml) of the intended volume, whereas
it was 75  5% (6.4/8.5 ml) for patients in group 2 and 81
 7% (6.9/8.5 ml) for patients in group 3 (Table 1). Differ-
ences between groups 1 and 2 (P  0.028) and groups 1 and
3 (P  0.02) were statistically significant, whereas the dif-
ference between groups 2 and 3 (P  0.52) was not.
The number of patients who received the entire intended
dose of chemotherapy was lowest in group 1. Indeed, the
entire dose of chemotherapy was given to 19% of the pa-
tients in group 1 (7/36 patients, 9 ml), 86% of the patients in
group 2 (78/91, 8.5 ml), and 91% of the patients in group 3
(30/33, 8.5 ml). The number of patients that received the
entire intended dose of chemotherapy was significantly
greater both in groups 2 and 3 than in group 1 (P  0.0001).
However, no difference was found between groups 2 and 3
(P  0.46).
Arterial patency was found to be greatest when the em-
bolic agents (PVA or Gelfoam) were administered at the end
of the procedure. In group 1, 56% of previously embolized
arteries were found to be recanalized at follow-up (Fig. 1),
whereas 74% and 81% (Fig. 2) of previously embolized
vessels in groups 2 and 3 had recanalized at follow-up. The
degree of recanalization was significantly greater in group 2
(Fig. 1) than in group 1 (P 0.05). However, no statistically
significant differences were observed between groups 2 and
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3 (P  0.42) and between groups 3 and 1 (P  0.07).
Despite the great difference in average recanalization be-
tween groups 1 and 3 (56% vs. 81%), the low number of
patients in groups 1 and 3 is likely to account for the lack of
statistical significance between the two groups.
Discussion
Transcatheter arterial chemoembolization was designed to
achieve regional tumor control by delivering high doses of
chemotherapeutic agents directly to the tumor site and slow-
ing down the transit time of these agents within the tumor.
The combination of intraarterial delivery of chemotherapy
and some degree of arterial embolization allowed for greater
drug concentration within the tumor, minimizing systemic
toxicity in the process [19, 20]. Despite its potency, chemo-
embolization has not been able to provide a cure for liver
cancer. However, it has proven effective at prolonging sur-
vival, especially in patients with hepatocellular carcinoma
and metastatic neuroendocrine tumors, and at providing
symptomatic relief [21, 22], justifying its usefulness as a
palliative tool against liver cancer.
After having gained experience using the TACE protocol
consisting of the slurry of chemotherapy, lipiodol and PVA,
we noted that the complete dose of chemotherapy could not
frequently be administered, often diminishing the efficacy of
TACE. This observation constituted the basis of our study.
Our results confirmed that a higher percentage of patients
received the entire dose of chemotherapy and that the mean
volume of injected chemotherapy was greater when the
embolic particles were injected at the end of the procedure.
Thus, if the goal of chemoembolization is to deliver the
highest possible dose of chemotherapy to the tumor, patients
treated with the slurry protocol may in fact have been de-
prived of the theoretical effects of the chemotherapeutic
agents. It is likely that early injection of PVA as part of the
slurry of chemotherapy, lipiodol and embolic material pre-
vented the chemotherapy from being delivered to the tumor.
On the other hand, when PVA particles were injected at the
end of the procedure, they had no impact on the dose of
chemotherapy delivered at the time of the chemoemboliza-
tion or during subsequent chemoembolizations.
The type of embolic material used (PVA or Gelfoam) did
not significantly affect the volume of chemotherapy admin-
istered since most patients received the intended dose of
chemotherapy (86% with PVA and 90% with Gelfoam).
Note that not all patients in these groups received the entire
amount of chemotherapy. This is likely due to the emboli-
zation effects of the lipiodol, which can reduce arterial
inflow to the tumor, especially further distally.
To account for these factors, Matsuo et al. [23] matched
the volume of lipiodol used in chemoembolization to tumor
size and vascularity. They found that tumor necrosis was
maximized when the injected volume of lipiodol (in ml) was
less than tumor diameter (in cm) for tumors larger than 5 cm.
Our study supports Matsuo’s findings, since the embolic
effects of lipiodol occasionally prevented administration of
Fig. 1. (A) Selective digital subtraction arteriogram, via
microcatheter, prior to chemoembolization with a slurry of
PVA, chemotherapy, and ethiodol. This patient was treated
for metastatic carcinoid tumor. (B) Selective digital
subtraction arteriogram acquired 7 weeks later, showing
minimal recanalization of the previously embolized arteries.
114 J.-F.H. Geschwind et al.: Chemoembolization of Liver Tumors
the complete dose of chemotherapy for some patients. Re-
duction of the lipiodol volume may have allowed increased
delivery of chemotherapy, thereby facilitating a greater tu-
mor response. The approach described by Matsuo may be
warranted to ensure delivery of the entire dose of chemo-
therapy.
Some controversy continues to surround the relative
amounts of embolization and chemotherapy that should be
used to optimally treat liver cancer. In fact, the precise
effects of embolization on tumor cells remain largely un-
known. In a recent study, Kobayashi et al. [24] found that
blood levels of vascular endothelial growth factor were
markedly increased in patients who had been treated with
embolization, suggesting a direct link among the degree of
embolization, tumor hypoxia, and the stimulation of new
blood vessels [24]. However, the impact of embolization on
the patency of arteries directly responsible for feeding the
tumor has not been evaluated. Whereas some studies have
reported excellent results with embolization alone (mostly
against neuroendocrine tumors), others support the use of
Fig. 2. (A) Digital subtraction image of a diagnostic
visceral arteriogram, obtained prior to the initial
chemoembolization. Note that the hepatic arteries are
widely patent. This patient was treated for a
neuroendocrine tumor, metastatic to the liver. (B) Selective
digital subtraction arteriogram, via microcatheter,
immediately after chemoembolization using Gelfoam as the
embolic material, administered at the end of the procedure.
Note that the tumor vessels are occluded. (C) Selective
digital subtraction arteriogram acquired 8 weeks after
chemoembolization, shown in Figure 2b, showing complete
recanalization of the treated arteries.
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chemotherapy as a part of a cocktail, containing an oily
vehicle and embolic particles, delivered to the tumor [6, 25,
26].
Several reports have shown TACE to be much more
effective when administered multiple times as opposed to a
single treatment, since those patients demonstrate a greater
degree of tumor necrosis [27, 28]. Since recanalization of
tumor vasculature is a prerequisite to subsequent TACE
procedures, determination of the long-term effects of em-
bolic agents is of critical importance. Our study suggests that
the type of chemoembolization protocol rather than the type
of embolic material had a significant impact on the rate of
arterial recanalization or arterial patency. Indeed, when the
slurry of chemotherapy, lipiodol and PVA particles was
used, only 56% of previously embolized vessels were found
to be patent at subsequent TACE procedures. However,
when the PVA particles were administered separately at the
end of the procedure, 74% of vessels remained patent. This
was also true when Gelfoam pledgets were used (81% pa-
tency) in the same manner. These results are somewhat
surprising since it has long been believed the embolization
with PVA particles results in more permanent vessel occlu-
sion than that with Gelfoam [29]. Because of their smaller
size (150 m), PVA particles are supposed to penetrate
deeply into the vascular bed of the tumor, resulting in more
distal and permanent vascular occlusion than encountered
with Gelfoam pledgets. However, PVA particles do not
appear to influence the patency of the main feeding vessel, as
our study suggests.
The timing of embolic particle administration during che-
moembolization has a significant impact on both the inject-
able volume of chemotherapy and subsequent arterial
patency. This study does have limitations, since we did not
randomize patients to various protocols, and we have not
analyzed patient outcomes for each protocol. However, we
believe these data show that the administration of PVA
particles along with chemotherapy and lipiodol as part of a
slurry effectively reduces the potential efficacy of chemo-
embolization, since less chemotherapy could be injected.
This protocol also limits the benefits of subsequent chemo-
embolization therapy because of reduced arterial patency.
Therefore, based on these results, we favor the use of em-
bolic agents with the last dose of TACE.
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